[en] In this paper we propose guidelines for clinical trials aimed at assessing the efficacy of drugs for acute non-specific low back pain (LBP) with or without radicular pain, preliminary to their approval and registration. To this end, consensus statements were obtained from a group of experts in the fields of rheumatology, clinical medicine, public health and epidemiology. EBM resources were systematically used as references.
Disciplines :
Rheumatology
Author, co-author :
Devogelaer, J. P.
Dreiser, R. L.
Abadie, Eric ; Université de Liège - ULiège > Epidémiologie et santé publique
Avouac, Bernard ; Université de Liège - ULiège > Unité d'exploration du métabolisme osseux
Bouvenot, G.
Abello, J. C.
Kaufman, J. M.
Koes, B. W.
Laslop, A.
Lemmel, E.
Richy, F.
Rozenberg, S.
Tavares, V.
Valat, J. P.
Reginster, Jean-Yves ; Université de Liège - ULiège > Département des sciences de la santé publique > Epidémiologie et santé publique
DEYO RA: Drug therapy for back pain. Which drugs help which patients ? Spine 1996; 21: 2840-9.
KOES BW, van TULDER MW, OSTELO R, BURTON AK, WADDELL G: Clinical guidelines for the management of low back pain in primary care. An international comparison. Spine 2001; 26: 2504-14.
DEYO RA, WEINSTEIN JM: Low back pain. N Engl J Med 2001; 334: 363-70.
ABENHAIM L, ROSSIGNOL M, VALAT JP et al.: The role of activity in the therapeutic management of back pain. Report of the International Paris Task Force on Back Pain. Spine 2000; 25 (Suppl. 4): 1S-33S.
Note for guidance on clinical investigation of medicinal products for treatment of pain. Committee for Proprietary Medicinal Products (CPMC). The European Agency for the Evaluation of Medicinal Products (EMEA), London.
DEYO RA, BATTIE M, BEURSKENS AJHM et al.: Outcome measures for low back pain research. A proposal for standardized use. Spine 1998; 23: 2003-13.
DREISER RL, MARTY M, IONESCU E, GOLD MS, LIU J-M: Relief of moderate to severe low back pain with diclofenac-K 12.5 mg tablets: A multiple flexible dose, ibuprofen, placebo controlled trial. Pharmacy and Pharmaceutical Sciences World Congress 2002 (abstract PS-P-008).
ANNICK BC 3rd, LERNER D, ROGERS WH, ROONEY T, KATZ JN: A review of health-related work outcome measures and their uses, and recommended measures. Spine 2000; 25: 3152-60
GHOZLAN R, DROPSY R: Etude de l'activité antalgique (en dose unique) de l'etodolac per os, du tenoxicam I.M. et du placebo dans la lombosciatique aiguë. Rhumatologie 1996; 48: 83-90.
HATORI M, KOKUBUN S: Clinical use of etodolac for the treatment of lumbar disc herniation. Curr Med Res Opin 1999; 15: 193-201.
DREISER R-L, Le PARC JM, VÉLICITAT P, LLEU PL: Oral meloxicam is effective in acute sciatica: two randomised, double-blind trials versus placebo or diclofenac. Inflamm Res 2001; 50 (Suppl. I): S17-S23.
WEBER H, HOME I, AMLIE E: The natural course of acute sciatica with nerve root symptoms in a double-blind placebo-controlled trial evaluating the effect of piroxicam. Spine 1993; 18: 1433-8.
VAN TULDER MW, SCHOLTEN RJ, KOES BW, DEYO RA: Non-steroidal antiinflammatory drugs for low back pain. Cochrane Database Syst Rev 2000; 2: CD 000396.
